Most people with less common forms of Alzheimer's disease would not qualify for the anti-amyloid drugs designed to slow it, according to research published August 5 in Neurology.
Among 184 people with biomarker-confirmed atypical Alzheimer's disease, between 70 and 85 percent would not meet the eligibility criteria for lecanemab or donanemab, the study found. Many of them were still in the early stages of their disease and could manage many daily activities.
